INORGANIC MINERAL COMPOSITION

Abstract: A composition for use in a method for treatment of the human or animal body by therapy method comprising: the mixture in parts by weight of: (a) aluminium oxide hydrate about 18 parts iron about 11 parts magnesium oxide about 5 parts silicon dioxide about 1.5 parts sodium hydroxide about 1 part potassium hydroxide about 1 part including trace amounts of copper, zinc, and calcium, with the balance of the mixture comprising ammonium sulfate, optionally with a pharmaceutically acceptable carrier or diluent or (b) aluminium oxide hydrate about 17 parts iron about 8 parts magnesium oxide about 5 parts silicon dioxide about 1.5 parts sodium hydroxide about 1 part potassium hydroxide about 1 part including trace amounts of copper, zinc, and calcium, with the balance of said mixture comprising ammonium sulfate.

Description: The present invention relates to the treatment of various disorders of the skin, including fungal infections, as well as to the treatment of certain inflammatory and internal disorders and infections. More particularly, it relates to the treatment of skin, inflammatory and internal disorders through the use of a topically applied or orally ingested pharmaceutical composition comprising a mixture of aluminum, iron, magnesium and other mineral compounds. The following skin disorders may be treated in accordance with the present invention: psoriasis, dermatitis, dandruff, eczema, ichthyosis, athlete's foot, acne, fungus infections, scabies, skin rashes, scleroderma, hair loss (other than that due to inherited male pattern baldness) moles/warts and cysts. Superficial fungal infections of the skin, toe nails and finger nails may also be treated. Inflammatory disorders, which may be treated with compositions according to the invention may share common features with one or more of the skin disorders listed above and include hemorrhoids, inflammatory dermatoses and similar conditions. Specific skin disorders and inflammatory conditions treated are illustrated by the following non-exhaustive list: Cysts - abnormal sacs containing a gas, fluid or semi-solid material including cysts of the dermis such as epidermal cysts of the inclusion or implantation type; Dermatitis - an inflammation of the skin caused by many sources including skin sensitivity to light (sunlight), chemicals, perfumes, allergies to various plants and animals including contact type dermatitis, exfoliative, seborrheic dermatosis or eczema; Hemorrhoids - a varicose condition of the external hemorrhoidal veins causing painful swellings at the anus, both internal, when the swollen veins are beneath the mucous membrane within the external sphincter, and external when the dilated veins form tumors to the outer side of the sphincter; Moles - including benign intradermal nevi and compound nevi; Psoriasis - a condition characterized by the eruption of circumscribed, discrete and confluent silver scaled skin occurring primarily on the elbows, knees, scalp, and trunk. Superficial fungal infections treated in accordance with the invention include ringworn (tinea) of various body parts including nails, scalp, groin, beard and feet (athlete's foot). Conventional regimens of therapy have dealt with many of these conditions in a variety of ways, e.g., surgically, topically and systemically. For a summary of such approaches, see The Merck Manual , 14th Edition (1982). The methods and compositions of this invention represent a marked departure from these prior treatments. Pharmaceutical presentation --The compositions of the invention may be administered in any convenient topical, oral or rectal form in suitable pharmaceutical vehicle or as a powder. Suitable pharmaceutical vehicles are well known in the art according to the type of preparation desired. Thus, for example, tablets, capsules, ingestible liquids or powder preparations, topical liquids and powder preparation, creams, ointments, salves, lotions for topical application and suppositories can be prepared as required. The optimum pharmaceutical presentation is conveniently determined empirically by one skilled in the art of compounding pharmaceutical preparations. Also included within the presentations contemplated by this invention are dietary mineral supplements to be taken by the patient to supplement his/her daily mineral intake. Such presentations typically take the form of orally-ingested preparations such as tablets and capsules. It will be understood that because the elements present are not toxic the absolute quantity of active ingredients present in any dosage unit or unit of application may or may not exceed that appropriate to the rate and manner of administration to be employed and should desirably be adequate to allow the intended rate of administration to be achieved by a larger or smaller number of doses or applications. The rate of administration will, moreover, depend on the condition being treated, the form of pharmaceutical presentation(s) employed, and the precise pharmacological action desired. Veterinary formulations and presentations are also included within the scope of the present invention, and in addition to those presentations noted above intended primarily but not exclusively for human use, suitable formulations include feed supplements and additives, chewable flavored tablets and capsules. A preferred form is to blend the compound of aluminum, iron, magnesium and other elements with the animal's food for administration in the form of a mash, pellet, granule or other convenient style. Vitamins, minerals, antibiotics, antioxidants, and other pharmacologically active compounds of the type contained in domestic animal feeds may also be included. The essential component of the pharmaceutical compositions and methods of treatment herein described is a mineral compound and mixture of inorganic oxides containing principally the oxides of aluminum and magnesium together with iron (believed to be in the from of iron hydroxide) with minor amounts of the oxides or hydroxides of silicon, sodium and potassium together with trace amounts of other elements such as calcium, zinc and copper. A more detailed analysis is given below. The particular mixture of the inorganic mineral compound employed in my invention is isolated from a Nevada (U.S.A) ore containing the required elements. Once removed from the ground the ore is crushed to a fine powder and sized, treated with a minor amount of sulfuric acid and heated to form a suspension. The pH is adjusted with a base such as ammonium hydroxide, filtered, dried and again pulverized. Complete details of treating the ore to give the desired product are given below. X-ray diffraction analysis and atomic absorption spectrometry define the composition as follows: Composition Wt % Parts By Wt. Ammonium Sulfate 83.0 198.0 Aluminum Oxide Hydrate Al(OH)₃ 7.25 17.3 Magnesium Oxide MgO 1.99 4.7 Iron hydroxide 3.33 7.9 Silicon Dioxide SiO₂ 0.62 1.5 Sodium Hydroxide NaOH 0.42 1.0 Potassium Hydroxide KOH 0.46 1.1 Free Water at 40°C (105°F) H₂O 2.53 6.0 Trace amounts of calcium, zinc and copper were detected. Proportions of the various ingredients may vary ± a few percent of the value stated. That is, the precise values given above may vary up to ±1.5% for the aluminum and magnesium oxides and iron and ±0.5% for the remaining oxides and hydroxides present. Unless otherwise indicated, all parts and percentages given throughout this specification and in the appended claims are by weight. Preparation Of The Inorganic Mineral Powder The following is a typical procedure for preparing the inorganic mineral powder used in the present invention: 1. The inorganic mineral powder is extracted from ore in a Placer mining claim in Nevada. After removal of two feet of overburden, the ore is removed by excavation and run through a jaw crusher which evens out the mesh size and removes lumps which are present. 2. The ore is then pulverized and the mesh size further reduced to at least minus forty mesh (Tyler) screen. 3. A solution composed of 14% H₂SO₄ and 86% water (deionized) is mixed together in a vessel, i.e., a Pfaudler tank. Water from the water table below the surface of the mining claims is acceptable and can be used. After this is done, the fine ore is added to this solution at a ratio of 0.7 Kg (1.5 pounds) of ore for each 1.8 liters of solution. This ratio of ore to solution can be used up to any volume, limited only by the size of the vessel being used. Heating, pressurizing and agitating the contents of the treatment vessel shortens recovery time. 4. The aqueous ore mixture is then heated to a minimum of 121°C (250° F) to suspend the ore until the ore "pulp" turns to a light buff color. A scan can also be taken to assure that all of the elements to be recovered have been placed into suspension. Agitation of the ore in solution will speed up the process of placing the elements into suspension. However, this is not a requirement needed for successful recovery of the final product. 5. After the elements are in suspension, the heat is turned off and the solution containing the elements in suspension and the pulp, which will drop to the bottom of the container, is allowed to cool and stand overnight. 6. Separation of the solution from the pulp is then achieved by filtration, using Whatman No. 541 filter paper. Other filtration may also be used. 7. Ammonium hydroxide (NH₄OH) specific gravity 0.89 (26°Baume) is then carefully added to the solution, using MAG-MIX; the solution is stirred during this addition to avoid generating too much heat or any other unfavorable reaction. While this is being done, a pH probe is placed into the solution from time to time to maintain the pH between 7.5 and 8.0 but never below 7.5. The precipitate will have a rich brown color if all prior steps have been properly taken. 8. The solution is allowed to stand for a minimum of four hours and preferably overnight. The solution is then at ambient temperature and is again filtered, using Whatman No. 541 filter paper. 9. After removing the product from the filter paper into a clean heat resistant (PYREX) container of flat, rectangular shape, spreading the product evenly to allow uniformity in drying, the container is placed in an oven dryer at 124°C (255°F.) until the product is dry. A rotary dryer could also be used. 10. After drying, the product should be placed in closed container (desiccator) to prevent adsorption of moisture from air to eliminate lumping, the material is run through a plate pulverizer to -100 mesh (Tyler) which makes the product easy to place in capsules or mix with an emollient base for different types of pharmaceutical presentations. General Methods of Use -- One of the formulations described above is applied to the affected area, when topical application is indicated, and then allowed to remain in contact, often with the aid of a dressing or bandage, until the symptoms have improved. For hemorrhoids or other inflammatory conditions in the anorectal area a petroleum-based ointment or paste is applied or a suppository is inserted. For psoriasis, dermatitis, moles and cysts a water-soluble cream base allows the preparation to blend into the skin is desirable. Moles, cysts and fungus infections particularly in the toenail and fingernail area are advantageously treated with a petroleum-based ointment. Powders in accordance with the present invention are conveniently dusted onto the desired area while capsules and tablets are taken orally. Ointment bases suitable for preparing topically applied pharmaceutical preparations according to the invention are selected from the oleanginous bases, and which include animal and plant fats, petroleum hydrocarbons and silicones, absorption bases, emulsion bases, and water-soluble bases. Suitable ointment bases and procedures for ointment preparation are described in Remington's Pharmaceutical Sciences pp. 525-543, Mack Publishing Co. (1965). The invention is further illustrated with reference to the following pharmaceutical formulations: Ointment Equal quantities of the inorganic mineral powder are mixed with Aloe Vera Gel or with a petroleum jelly (Vaseline®) base using a steel spatula and glass ointment slab to make a smooth, semi-translucent ointment. Cream Equal quantities by weight of the inorganic mineral powder are mixed with Dermabase cream base using a spatula and ointment slab to make a smooth light brown, creamy ointment that upon application with rubbing is abosrbed into the skin. Powders The inorganic minerals are finely ground and sized into a free-flowing powder which is packaged in 113g (4 oz.) shaker containers suitable diluents and desiccants may be included as required. Capsules Gelatin capsules, ranging from size 00 to number 4 are filled with powdered inorganic minerals, a diluent being included as desired to adjust the active ingredient content per capsule. The following examples will serve to illustrate pharmaceutical compositions and methods of treatment in accordance with the present invention: Example 1--Treatment of Hemorrhoids A topical cream was prepared using the mineral compound distributed in an emollient, base. The paste contained the following ingredients by weight percent and parts by weight: Composition Weight % Parts By Weight Aluminum Oxide Hydrate 3.7 17.6 Iron hydroxide 2.285 10.9 Magnesium Oxide MgO 1.005 4.8 Silicon Dioxide SiO .31 1.5 Sodium Hydroxide NaOH .21 1.0 Potassium Hydroxide KOH .23 1.0 Trace Amounts of Copper, Zinc and Calcium Emollient Base 50.0 Free Water at 40°C (105°F) 1.265 Ammonium Sulfate (NH₄)₂SO₄ balance to 100% Example 2 A patient who had experienced acutely inflammed internal and external hemorroids was provided with the cream as described in Example 1 with instructions to apply the cream topically daily to the affected area. At the end of 4 weeks the itching and pain previously associated with the involved rectal tissue had subsided and the swollen tissue was reduced about 75% in size. Example 3--Treatment of Rectal Fissures A patient having a history of bleeding rectal fissures for the previous 2-3 years was given the cream as prepared in Example 1 with instructions to apply the cream topically to the affected area once a day and to continue the application until symptoms improved. At the end of 10 days the patient reported a 90% reduction in the bleeding and continued treatment resolved the symptoms. Example 4--Treatment of Tinea Pedis A man with a long standing fungal infection (Athlete's Foot) of the left foot and toenail intermittently self treated his foot with tolnaftate powder and liquid without particular success. Vesicles were observed on the left sole and a thickened, loosened medial half of the first toenail was noted. The left first toenail could easily be lifted away from the underlying skin. An ointment was prepared of 50 parts by weight of the mineral powders described in Example 1 uniformly distributed in an equal quantity of petroleum jelly (Vaseline®) base. The patient was given a supply of ointment and instructed to apply it to the toe and left foot areas followed by bandaging. The ointment remained in place 2-3 days then was removed with the dresssing and the foot left untreated for 2 weeks. The procedure was repeated 4 more times. When again seen by his dermatologist, the patient's left sole appeared to be free of abnormalities and his left first toenail was firmly attached. Example 5--Treatment of Psoriasis A white male having a history of psoritic lesions on his extremities and groin for the previous 3 years was prescribed the ointment product prepared in Example 4. Four topical applications of the ointment preparation in accordance with Example 4 were made over a 2 week period. At the conclusion of therapy the psoritic lesion had healed to smooth, clear epidermal tissue. Example 6--Treatment of Moles A patient was examined and a previously small mole on the forearm had become hyperplastic growing to about 3 times its original size. The mole's color changed from light brown to grey, and its texture from smooth to rough and granular. These changes occured over a period of about 60 days. The ointment of Example 4 was applied once, topically and bandaged. Approximately 2 days later the area of the lesion was examined. The area was clear, previously fixed pathological tissue was completely removed, and the underlying smooth epidermal surface showed no evidence of inflammation or abnormality 24 hours after this single application. Example 7--Preparation of Capsules Capsules for oral administration were prepared using an inorganic mineral powder containing the following ingredients: Composition % By Weight Parts by Weight Aluminum Oxide Hydrate Al(OH)₃ 3.7 17.3 Iron Fe 3.33 7.9 Magnesium Oxide MgO 1.99 4.7 Silicon Dioxide SiO 0.62 1.5 Sodium Hydroxide NaOH 0.42 1.0 Potassium Hydroxide KOH 0.46 1.1 The mineral powder also contained trace amounts of copper, zinc and calcium, with the balance to 100% being ammonium sulfate (NH₄) SO₄. Size 4 capsules were filled with the above powder, each capsule containing 231.2 mg of the powder. No fillers, additives or diluents are used. Example 8--Treatment of Arthritis and Bursitis A man suffering with chronic joint pain caused by bursitis and arthritis, unable to walk without the assistance of a cane, suffered pain and stiffness. His condition degenerated and over a period of time he was able to stand erect only for short periods of time. The patient began taking the capsules of Example 7, six capsules per day. Positive results were noted in a few days and at the end of three weeks of therapy the patient was able to walk for distances of as much as half a mile without the use of a cane, an accomplishment the patient had not been able to do in the past 3 years. The patient reports no adverse effects and has reduced intake to three capsules per day. Example 9--Treatment of Infectious Mononucleosis A woman, suffering from poor health for a period of some 12 years, was diagnosed as having infectious mononucleosis caused by Epstein-Bar virus, a condition characterized by high fever, sore throat, headache, fatigue and generalized lymphadenopathy. The patient began taking four of the capsules of Example 7 and within two days experienced an improvement in overall feeling. Her condition continues to improve with complete disappearance of symptoms of fatigue. Example 10--Treatment of Spastic Colitis A woman, suffering from lack of paristalic movement causing constipation relieved only by enemas, was diagnosed as having spastic colitis. The patient took 4 of the capsules of Example 7 per day for a period of two weeks. Over this period of time her bowel movements and blood counts returned to normal. Example 11--Treatment of Emphysema A woman suffering from severe emphysema for 8 years was essentially confined to bed. This patient began taking four capsules of Example 7 per day and within 4 weeks her docter reported no difficulty in finding a blood vein from which to remove an adequate blood sample, red blood cells and white blood cell counts returned to normal, and pulse rate at rest slowed from 80 to 59 beats per minute. The patient reports that she is no longer confined to bed and is able to walk around her house and enjoys a marked improvement in breathing. Example 12--Treatment of Prostate and Bone Cancer A patient, diagnosed as having malignant prostate cancer, was followed for a period of 3 years during which the patient additionally developed a tumor mass in the right pelvic wall. He continued to experience an overall decline in health and energy until he was no longer able to walk without pain; his general condition worsened and even further pain medication was required. The patient began to take the capsules of Example 7, six capsules per day, and within a period of 3 weeks there was a decrease in size of the tumor mass and associated pain also decreased. At the end of 3 months therapy the tumor mass was almost unpalpable, the patient's general strength improved greatly and the grey hair of the body and the head partially returned to its original black color. The patient always feels better taking the capsules than not. Example 13--Treatment of Cancer A patient was diagnosed as having terminal cancer; exploratory surgery, confirmed the diagnosis and no therapy or treatment was offered. About six months following diagnosis the patient began taking the capsules as described in Example 7, twelve capsules per day and his mental attitude, appetite and strength improved considerably. After seven months of therapy CAT scans revealed a measurable reduction in most of the tumors. After 11 months the patient was feeling wonderful and the liver cancer showed sucessive reductions with the last reduction 80%. The cancer in the pancreas lymph nodes, lungs, spleen and intestines was no longer present and had disappeared. Example 14--Treatment of Epidermoid Carcinoma A male patient with a mass on the left side of his neck had a major portion of it surgically removed. The mass was diagnosed as epidermoid (transitional) carcinoma. Because not all of the diseased tissue could be removed the patient was advised that his condition was terminal. The patient took the capsules described in Example 7, nine per day for a period of 26 days, after which a biopsy of the nasopharynx revealed no evidence of malignancy. The capsules were continued for about a 4 month period of time concurrent with cobalt radiation therapy. Although the radiation therapy caused considerable weight loss, it is believed that the inorganic dietary mineral supplement is responsible for the patient's cancer-free condition.

Claims: A composition for use in a method for treatment of the human or animal body by therapy comprising the mixture (in parts by weight): (a) aluminum oxide hydrate about 18 parts iron hydroxide about 11 parts magnesium oxide about 5 parts silicon dioxide about 1.5 parts sodium hydroxide about 1 part potassium hydroxide about 1 part including trace amounts of copper, zinc, and calcium, with the balance of the mixture comprising ammonium sulfate, optionally with a pharmaceutically acceptable carrier or diluent or (b) aluminum oxide hydrate about 17 parts iron hydroxide about 8 parts magnesium oxide about 5 parts silicon dioxide about 1.5 parts sodium hydroxide about 1 part potassium hydroxide about 1 part including trace amounts of copper, zinc, and calcium, with the balance of said mixture comprising ammonium sulfate. A composition according to claim 1 (a) for use in treating skin disorders, inflammatory conditions or hemorrhoids. A composition according to claim 2 in which the inflammatory condition is inflammatory dermatoses. A composition according to claim 2 in which the skin disorder is psoriasis, dermatitis, acne, a fungus infection, tinea pedis, tinea unguium, a nevus or a cyst. A composition according to claim 1 (b) for treating arthritis, bursitis, infectious mononucleosis, spastic colitis, emphysema or cancer. A composition according to claim 5 for treating prostrate or bone cancer or epidermoid (transitional) carcinoma. A process for preparing an inorganic mineral powder composition as defined in claim 1 (a) or (b) comprising the steps of: (1) extracting ore from a source of minerals; (2) pulverizing the thus extracted ore to a small particle size; (3) adding the pulverized ore from step (2) to an aqueous solution of sulfuric acid to form a suspension of ore in the aqueous solution; (4) heating the suspension of step (3) to at least about 250°F (= 120°C) until the ore becomes light brown in color; (5) cooling the thus-heated suspension, allowing the suspended particles to precipitate, and separating the supernatant liquid; (6) adding ammonium hydroxide to the separated supernatant with stirring and adjusting the pH to a value in the range of 7.5 up to about 8.5 and forming a brown colored precipitate; and (7) collecting, drying and pulverizing the precipitate. A pharmaceutical composition comprising as the active ingredient an inorganic mineral powder composition as defined in claim 1. A composition according to claim 8 in the form of an ointment comprising approximately equal weights of the active ingredient and an emollient base. Use of a composition as defined in any one of claims 1 to 6, a composition according to claim 8 or 9 or a pulverized inorganic mineral powder produced by the process of claim 7 for the manufacture of a medicament for a therapeutic application as defined in any one of claims 2 to 6.

Inventors: JENSEN, CHARLES ALLEN
Applicants: JENSEN, CHARLES ALLEN
Application year: 1986
Main classification: A61K35
IPC codes: A61K33, A61K35